Reflects Company’s Evolution to Offering Digital Health Framework Complementing its Capital Equipment Technologies IRVINE, Calif.–(BUSINESS WIRE)–Nihon Kohden, a U.S. market leader in precision medical products and services, today announced that it is rebranding Nihon Kohden USLab, its Irvine-based R&D and product development subsidiary, to Nihon Kohden Digital Health Solutions Inc. […]
Other News
Zynex Announces 2020 Fourth Quarter and Full Year Earnings
ENGLEWOOD, Colo., Feb. 25, 2021 /PRNewswire/ — 2020 Full Year Revenue increased 76% year over year to $80.1 million Orders increased 96% Net income of $9.1 million; Diluted EPS $0.26 Adjusted EBITDA $13.7 millio 2020 Revenue and Adjusted EBITDA are the highest in Company history 2020 Fourth Quarter Revenue increased 81% year over year to $25.6 million Orders […]
iRhythm Technologies Announces Fourth Quarter and Full Year 2020 Financial Results
SAN FRANCISCO, Feb. 25, 2021 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today reported financial results for the three months and full year ended December 31, 2020. Fourth Quarter 2020 Financial Highlights Revenue of $78.8 million […]
Cytokinetics Reports Fourth Quarter 2020 Financial Results
Company Plans to Meet with FDA in Q1 to Discuss Results of GALACTIC-HF Enrollment Completed in Cohort 2 of REDWOOD-HCM; Results Expected Mid-Year Company Provides 2021 Financial Guidance; More Than Two Years of Cash Runway SOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) reported […]
Caladrius Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
Company demonstrates resilience despite COVID-19 challenges: Financial situation secure and development programs progressing Conference call begins today at 4:30 p.m. (ET) BASKING RIDGE, N.J., Feb. 25, 2021 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies […]
Study Published in JAMA Finds Hospital Availability of TCAR Associated with an Improvement in Overall Outcomes for Carotid Revascularization
SUNNYVALE, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) — Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced positive results from a comparative-effectiveness study have been published in JAMA Network Open. The study found the availability of TCAR at a hospital […]
Silence Therapeutics and Mallinckrodt Initiate Work on Third Target as Part of Ongoing RNAi Research Collaboration for Complement-Mediated Diseases
Silence Therapeutics and Mallinckrodt Initiate Work on Third Target as Part of Ongoing RNAi Research Collaboration for Complement-Mediated Diseases Silence to receive $2 million research milestone payment Silence is also eligible to receive up to $2 billion in total milestone payments across all three targets and tiered double-digit royalties on […]
Acceleron Reports Fourth Quarter and Full Year 2020 Financial Results
– Updates from ongoing PULSAR and SPECTRA Phase 2 clinical trials of sotatercept in patients with pulmonary arterial hypertension (PAH) presented at the American Heart Association (AHA) 2020 Scientific Sessions – – STELLAR Phase 3 trial initiated with sotatercept in PAH – – Acceleron recognized approximately $23.0 million in royalty […]
Protembis Announces Completion of 20 Cases in European CE Mark Study With the ProtEmbo® Cerebral Protection System
Enrollment with advanced generation device for complete cerebral protection nearing halfway mark in clinical study in Germany and Poland AACHEN, Germany–(BUSINESS WIRE)–Protembis GmbH, a privately held emerging medical device company, announced today the successful completion of 20 clinical cases in its European regulatory study of the ProtEmbo® Cerebral Protection System. The […]
Teleflex Reports Fourth Quarter and Full Year 2020 Results; Provides 2021 Guidance
Fourth quarter 2020 revenues of $711.2 million, up 4.4% versus prior year period on an as-reported basis; up 2.3% on a constant currency basis Fourth quarter 2020 GAAP diluted EPS from continuing operations of $1.62, compared to $2.28 in the prior year period Fourth quarter 2020 adjusted diluted EPS from continuing […]



